{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:41Z","timestamp":1791613661223,"version":"4.3.4"},"reference-count":114,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In this review, we explore the role of complex interactions between genomic evolution, environmental and genetic predispositions, and immune surveillance in disease progression from precursor conditions smoldering multiple myeloma and monoclonal gammopathy of undetermined significance to multiple myeloma (MM). MM has been described to be universally preceded by precursor states, often decades before it is even diagnosed. Genetic predisposition plays an important role in the initial transformation, and is driven by both germline variants and MM-specific loci influencing risk. The reported disparities in occurrence of precursor conditions and MM among racial groups highlights the role of predisposition and the need for broader cohort studies. Early genomic events, such as translocations and hyperdiploidy, are essential in precursor initiation. However, additional factors are usually needed to transform the precursor stages into symptomatic disease, such as positive selection of subclonal populations. This process is affected by aging and environmental factors, such as exposures to Agent Orange and agrochemicals. Therefore, integrating genomic and transcriptomic data with immune profiling or other clinical features is essential for identifying patients with high risk of progressing into MM. Here, we highlight the complexity of myelomagenesis, and underline the importance of state-of-the-art approaches for improved disease prediction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026313","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T19:14:21Z","timestamp":1765221261000},"page":"1423-1432","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Evolution of multiple myeloma from a genomic perspective"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"first","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Samur","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"3VA Boston Healthcare System, Boston, MA"},{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026032611215051200_bib1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026032611215051200_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-20-1395","article-title":"Designing evolutionary-based interception strategies to block the transition from precursor phases to multiple myeloma","volume":"27","author":"Maura","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026032611215051200_bib3","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026032611215051200_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"2026032611215051200_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"2026032611215051200_bib6","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2026032611215051200_bib7","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026032611215051200_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2026032611215051200_bib9","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","article-title":"Genomic landscape of multiple myeloma and its precursor conditions","volume":"57","author":"Alberge","year":"2025","journal-title":"Nat Genet"},{"issue":"7","key":"2026032611215051200_bib10","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-20-2245","article-title":"Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001","volume":"27","author":"Maura","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026032611215051200_bib11","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2026032611215051200_bib12","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"2026032611215051200_bib13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood.2024025250","article-title":"Development of hyperdiploidy starts at an early age and takes a decade to complete","volume":"145","author":"Samur","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026032611215051200_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026032611215051200_bib15","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41588-025-02292-1","article-title":"Temporal genomic dynamics shape clinical trajectory in multiple myeloma","volume":"57","author":"Maura","year":"2025","journal-title":"Nat Genet"},{"issue":"13","key":"2026032611215051200_bib16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra2412716","article-title":"Monoclonal gammopathy of undetermined significance","volume":"393","author":"Rajkumar","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"2026032611215051200_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41588-022-01280-z","article-title":"Notch1 mutations drive clonal expansion in normal esophageal epithelium but impair tumor growth","volume":"55","author":"Abby","year":"2023","journal-title":"Nat Genet"},{"issue":"4","key":"2026032611215051200_bib18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41588-025-02125-1","article-title":"Selection for somatic escape variants in SERPINA1 in the liver of patients with alpha-1 antitrypsin deficiency","volume":"57","author":"Brzozowska","year":"2025","journal-title":"Nat Genet"},{"issue":"8058","key":"2026032611215051200_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-025-08708-6","article-title":"The somatic mutation landscape of normal gastric epithelium","volume":"640","author":"Coorens","year":"2025","journal-title":"Nature"},{"issue":"4","key":"2026032611215051200_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41568-021-00335-3","article-title":"Clonal expansion in non-cancer tissues","volume":"21","author":"Kakiuchi","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"6512","key":"2026032611215051200_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"issue":"6417","key":"2026032611215051200_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1126\/science.aau3879","article-title":"Somatic mutant clones colonize the human esophagus with age","volume":"362","author":"Martincorena","year":"2018","journal-title":"Science"},{"issue":"7876","key":"2026032611215051200_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-021-03822-7","article-title":"The mutational landscape of human somatic and germline cells","volume":"597","author":"Moore","year":"2021","journal-title":"Nature"},{"issue":"7881","key":"2026032611215051200_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","article-title":"Convergent somatic mutations in metabolism genes in chronic liver disease","volume":"598","author":"Ng","year":"2021","journal-title":"Nature"},{"issue":"11","key":"2026032611215051200_bib25","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"issue":"1","key":"2026032611215051200_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(24)00598-9","article-title":"The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study","volume":"26","author":"Santarsieri","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8040","key":"2026032611215051200_bib27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41586-024-08128-y","article-title":"Clonal dynamics after allogeneic haematopoietic cell transplantation","volume":"635","author":"Spencer Chapman","year":"2024","journal-title":"Nature"},{"issue":"24","key":"2026032611215051200_bib28","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"2026032611215051200_bib29","first-page":"1","article-title":"Studies on \u201cabnormal\u201d serum globulins (M-components) in myeloma, macroglobulinemia and related diseases","volume":"367","author":"Heremans","year":"1961","journal-title":"Acta Med Scand Suppl"},{"issue":"5","key":"2026032611215051200_bib30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"5","key":"2026032611215051200_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.0954-6820.1984.tb05032.x","article-title":"Benign monoclonal gammapathy","volume":"216","author":"Waldenstr\u00f6m","year":"1984","journal-title":"Acta Med Scand"},{"issue":"6","key":"2026032611215051200_bib32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1056\/NEJMoa075290","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"359","author":"Rawstron","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"2026032611215051200_bib33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N Engl J Med"},{"issue":"26","key":"2026032611215051200_bib34","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2026032611215051200_bib35","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2026032611215051200_bib36","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026032611215051200_bib37","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2018.0509","article-title":"Multiple myeloma and its precursor disease among firefighters exposed to the World Trade Center disaster","volume":"4","author":"Landgren","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"2026032611215051200_bib38","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent orange exposure and monoclonal gammopathy of undetermined significance: an operation Ranch Hand Veteran cohort study","volume":"1","author":"Landgren","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"2026032611215051200_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-021-00489-1","article-title":"Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18-40 years old: a possible HIV indicator condition","volume":"11","author":"Bibas","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026032611215051200_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2026032611215051200_bib41","doi-asserted-by":"crossref","first-page":"e98259","DOI":"10.1172\/jci.insight.98259","article-title":"Antigen-mediated regulation in monoclonal gammopathies and myeloma","volume":"3","author":"Nair","year":"2018","journal-title":"JCI Insight"},{"issue":"25","key":"2026032611215051200_bib42","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the agricultural health study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2026032611215051200_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/bloodadvances.2019000491","article-title":"A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry","volume":"4","author":"Du","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026032611215051200_bib44","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/s41467-024-50932-7","article-title":"Deciphering the genetics and mechanisms of predisposition to multiple myeloma","volume":"15","author":"Went","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"2026032611215051200_bib45","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2643-3230.BCD-23-0208","article-title":"Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes","volume":"5","author":"Thibaud","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2026032611215051200_bib46","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.3101","article-title":"Genome-wide analysis of noncoding regulatory mutations in cancer","volume":"46","author":"Weinhold","year":"2014","journal-title":"Nat Genet"},{"issue":"7605","key":"2026032611215051200_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"issue":"4","key":"2026032611215051200_bib48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"2026032611215051200_bib49","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1038\/s41467-019-11037-8","article-title":"A practical guide for mutational signature analysis in hematological malignancies","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2026032611215051200_bib50","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-021-25469-8","article-title":"Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma","volume":"12","author":"Maclachlan","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"2026032611215051200_bib51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/bloodadvances.2016003111","article-title":"Direct evidence for a polygenic etiology in familial multiple myeloma","volume":"1","author":"Halvarsson","year":"2017","journal-title":"Blood Adv"},{"issue":"19","key":"2026032611215051200_bib52","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1002\/cncr.30777","article-title":"Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles","volume":"123","author":"Bolli","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"2026032611215051200_bib53","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"24","key":"2026032611215051200_bib54","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026032611215051200_bib55","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"issue":"3","key":"2026032611215051200_bib56","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"issue":"9","key":"2026032611215051200_bib57","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"issue":"6","key":"2026032611215051200_bib58","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2026032611215051200_bib59","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026032611215051200_bib60","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","article-title":"Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes","volume":"184","author":"Dentro","year":"2021","journal-title":"Cell"},{"issue":"11","key":"2026032611215051200_bib61","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2026032611215051200_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2026032611215051200_bib63","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2026032611215051200_bib64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2026032611215051200_bib65","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"2026032611215051200_bib66","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2021011452","article-title":"IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM","volume":"138","author":"Bazarbachi","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2026032611215051200_bib67","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2026032611215051200_bib68","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.2024024299","article-title":"The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma","volume":"144","author":"Cirrincione","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026032611215051200_bib69","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"2026032611215051200_bib70","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"1","key":"2026032611215051200_bib71","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"2026032611215051200_bib72","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41375-019-0689-0","article-title":"Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma","volume":"34","author":"Maura","year":"2020","journal-title":"Leukemia"},{"issue":"27","key":"2026032611215051200_bib73","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.20.00461","article-title":"Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group","volume":"38","author":"Samur","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7924","key":"2026032611215051200_bib74","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41586-022-05072-7","article-title":"Diverse mutational landscapes in human lymphocytes","volume":"608","author":"Machado","year":"2022","journal-title":"Nature"},{"issue":"9","key":"2026032611215051200_bib75","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026032611215051200_bib76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2026032611215051200_bib77","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1038\/s41467-022-30694-w","article-title":"Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes","volume":"13","author":"Bustoros","year":"2022","journal-title":"Nat Commun"},{"issue":"21","key":"2026032611215051200_bib78","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026032611215051200_bib79","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","article-title":"MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology","volume":"13","author":"Dutta","year":"2023","journal-title":"Cancer Discov"},{"issue":"9","key":"2026032611215051200_bib80","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"2026032611215051200_bib81","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2026032611215051200_bib82","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","article-title":"Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease","volume":"41","author":"Dang","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"2026032611215051200_bib83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"3","key":"2026032611215051200_bib84","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO-25-01733","article-title":"Genomics define malignant transformation in myeloma precursor conditions","volume":"44","author":"Maura","year":"2026","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026032611215051200_bib85","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1056\/NEJMe2504273","article-title":"Targeting the tumor and the immune system in smoldering multiple myeloma","volume":"392","author":"Maura","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026032611215051200_bib86","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2026032611215051200_bib87","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"2026032611215051200_bib88","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","article-title":"Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)","volume":"100","author":"Khan","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2026032611215051200_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2026032611215051200_bib90","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2026032611215051200_bib91","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/bloodadvances.2024015680","article-title":"Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma","volume":"9","author":"Potdar","year":"2025","journal-title":"Blood Adv"},{"issue":"15","key":"2026032611215051200_bib92","doi-asserted-by":"crossref","first-page":"e167629","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J Clin Invest"},{"issue":"1","key":"2026032611215051200_bib93","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"issue":"104","key":"2026032611215051200_bib94","doi-asserted-by":"crossref","first-page":"eadp6667","DOI":"10.1126\/sciimmunol.adp6667","article-title":"Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma","volume":"10","author":"Lutz","year":"2025","journal-title":"Sci Immunol"},{"issue":"suppl 1","key":"2026032611215051200_bib95","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/blood-2024-208837","article-title":"Single-cell RNA-sequencing of 6 million tumor and immune cells in 365 patients with MGUS and SMM demonstrates complex progressive changes in immune cell functionality with a distinct footprint on tumor cell biology and disease control","volume":"144","author":"Sklavenitis-Pistofidis","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026032611215051200_bib96","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"key":"2026032611215051200_bib97","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"2026032611215051200_bib98","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2026032611215051200_bib99","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41591-020-1033-y","article-title":"Genomic copy number predicts esophageal cancer years before transformation","volume":"26","author":"Killcoyne","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"2026032611215051200_bib100","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41588-024-01988-0","article-title":"Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations","volume":"56","author":"Williams","year":"2024","journal-title":"Nat Genet"},{"issue":"10","key":"2026032611215051200_bib101","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026032611215051200_bib102","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2026032611215051200_bib103","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"2026032611215051200_bib104","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"2026032611215051200_bib105","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026032611215051200_bib106","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2026032611215051200_bib107","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41467-024-55308-5","article-title":"Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial","volume":"16","author":"Nadeem","year":"2025","journal-title":"Nat Commun"},{"issue":"11","key":"2026032611215051200_bib108","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"issue":"18","key":"2026032611215051200_bib109","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"27","key":"2026032611215051200_bib110","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.23.02771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","volume":"42","author":"Mateos","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026032611215051200_bib111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"19","key":"2026032611215051200_bib112","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-24-0210","article-title":"Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma","volume":"30","author":"Kazandjian","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026032611215051200_bib113","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-024-01053-3","article-title":"The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression","volume":"14","author":"Medina-Herrera","year":"2024","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026032611215051200_bib114","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/13\/1423\/2510753\/blood_bld-2024-026313-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/13\/1423\/2510753\/blood_bld-2024-026313-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:22:10Z","timestamp":1774538530000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/13\/1423\/557128\/Evolution-of-multiple-myeloma-from-a-genomic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":114,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026313","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,26]]},"published":{"date-parts":[[2026,3,26]]}}}